← Leaderboards
Amanda Stolarz
Univ Of Arkansas For Med Scis
$1,938,006
Attributed
$1,938,006
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $420.4K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,938,006 · 2
By mechanism
R37$1,054,741 · 1
P20$883,265 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “New Therapeutic Target”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Kathleen Maletic Neuzil · Emory University$26,258,144
- Priyamvada Acharya · Duke University$26,203,983
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
New Therapeutic TargetOptical ImagingMitochondriaMuscle CellsLymphedemaMediatingIn VivoInjuryLymphLymphatic CirculationGenerationsLymphatic VesselLymph FlowMalignant Breast NeoplasmAcuteDoxorubicinClinically RelevantImpairmentComplicationLiquid SubstanceBreast Cancer TherapyLymphaticBreast SurgeryPeriodicity
Grant awards (7)
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction$368,387
R37 · FY2025 · CA · contact PI
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction$334,377
R37 · FY2024 · CA · contact PI
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction$351,977
R37 · FY2023 · CA · contact PI
Mechanism and Prevention of Doxorubicin-Induced Lymphedema$68,400
P20 · FY2023 · GM · contact PI
Mechanism and Prevention of Doxorubicin-Induced Lymphedema$267,665
P20 · FY2022 · GM · contact PI
Mechanism and Prevention of Doxorubicin-Induced Lymphedema$273,600
P20 · FY2021 · GM · contact PI
Mechanism and Prevention of Doxorubicin-Induced Lymphedema$273,600
P20 · FY2020 · GM · contact PI